



**TEXAS**  
Health and Human  
Services

---

**Texas Department of State  
Health Services**

# **PHFPC Briefing**

---

**Texas Department of State Health Services**

**October 18, 2023**



**TEXAS**  
Health and Human  
Services

---

**Texas Department of State  
Health Services**

# **DSHS Organizational Structure Changes**

---


**Imelda Garcia, MPH**

**Senior Advisor**

**Office of the Commissioner**

**Texas Department of State Health Services**

**October 18, 2023**





**TEXAS**  
Health and Human  
Services

---

**Texas Department of State  
Health Services**

# **Update on COVID-19 Vaccine Administration**

---

**Josh Hutchison**

**Associate Commissioner**

**Infectious Disease Prevention Division**

**Texas Department of State Health Services**

**October 13, 2023**

# DISCLAIMER

The information presented today is based current preliminary data and on CDC's recent guidance. Information is subject to change.

October 18, 2023



**TEXAS**  
Health and Human  
Services

---

Texas Department of State  
Health Services

# **Updated 2023-2024 COVID-19 Vaccines**

---

# Updated 2023-2024 COVID-19 Vaccines



TEXAS

Health and Human Services

Texas Department of State  
Health Services

- September 11, 2023, the Food and Drug Administration (FDA) submitted the following press release highlighting:
  - Bivalent mRNA COVID-19 vaccines are no longer authorized
  - Approval and authorization of updated 2023-2024 COVID-19 vaccines targeting XBB.1.5 sub-lineage
- September 12, 2023, CDC's Advisory Committee on Immunization Practices (ACIP) issued updated [clinical guidance for COVID-19 vaccination](#).
- September 19, 2023, the new COVID-19 2023-2024 formulations went live in the Vaccine Allocation and Ordering System (VAOS) for all TVFC/ASN providers.
- These are the first COVID-19 vaccines to be available directly from the manufacturers as part of the commercial market, rather than through the United States Government for those providers not involved in programs within DSHS.
- October 3, 2023, the FDA authorized the updated 2023-2024 Novavax COVID-19 for individuals  $\geq 12$  yrs and ACIP updated the clinical guidance in accordance with this.



# COVID-19 Vaccine Program Transition to Texas Vaccines for Children (TVFC) Program



TEXAS

Health and Human Services

Texas Department of State  
Health Services

- The COVID-19 vaccines are now available under the TVFC program.
- TVFC program patient eligibility for all ACIP-recommended vaccines, including COVID-19, is birth through 18 years of age who are:
  - Uninsured
  - Underinsured
  - Children's Health Insurance Program (CHIP) - enrolled
  - Medicaid-enrolled/Medicaid-eligible
  - American Indian or Alaskan Native
- TVFC providers can charge an administrative fee up to \$13.75 for the COVID-19 vaccine however must not:
  - Deny administration of a TVFC vaccine to an eligible child because of the inability of the child's parent/guardian to pay the administration fee.
  - Charge an administration fee to Medicaid or CHIP patients.
  - Send a patient to collection or charge additional fees for non-payment of a TVFC administration fee.



# COVID-19 Vaccine Program Transition to Adult Safety Net (ASN) Program



TEXAS

Health and Human Services

Texas Department of State  
Health Services

- COVID-19 vaccines are now available under the ASN program.
- ASN program patient eligibility for the COVID-19 vaccine is 19 years of age and older who are uninsured or underinsured.
  - Uninsured - a person who does not have Medicare, Medicaid, or private insurance.
  - Underinsured - a person who has health insurance, but the insurance does not cover COVID-19 vaccines; a person whose medical insurance does not provide first-dollar coverage (i.e., copay-free coverage) of COVID-19 vaccinations.
    - First-dollar coverage: Refers to health care services, such as COVID-19 vaccinations, covered pre-deductible and without any cost-sharing.
- ASN providers cannot charge an administration fee for the COVID-19 vaccine.

# Updated 2023-2024 COVID-19 Vaccination Data Texas, 9/12/2023 – 10/15/2023



TEXAS

Health and Human Services

Texas Department of State  
Health Services

Age Group	Number of Updated 2023-2024 COVID-19 Vaccine Doses Administered* (September 12, 2023 – October 15, 2023)
6 months – 4 years	918
5-11 years	3,795
12-17 years	13,787
18-49 years	79,530
50-64 years	97,974
65+ years	215,731
<b>Total</b>	<b>411,735</b>

\*Data as of October 15, 2023 from Texas Immunization Registry



**TEXAS**  
Health and Human  
Services

---

**Texas Department of State  
Health Services**

# 2023 Mpox Update

---

**Varun Shetty, MD, MBA, MS**

**Chief State Epidemiologist**


**Office of the Chief State Epidemiologist**

**Josh Hutchison**

**Associate Commissioner**

**Infectious Disease Prevention Division**

# Average Mpox Cases Reported per Day by Week 10/9/2022 to 10/8/2023



# Mpox Situation Report Surveillance (01/01/2023 through 10/8/2023)




TEXAS

Health and Human Services

Texas Department of State  
Health Services

Cases by Public Health Region				
	Confirmed	Probable	Total Cases	% of Total Cases
1				
2/3	37	31	68	51.5%
4/5N				
6/5S	14	8	22	16.7%
7	10	22	32	24.2%
8	suppressed*		8	6.1%
9/10	suppressed*			
11	suppressed*			
UNK				
<b>Total</b>	<b>63</b>	<b>69</b>	<b>132</b>	<b>100.0%</b>



	# of Cases	% of Cases	
<b>&lt;18 Years</b>	0	0.0%	
<b>18-29 Years</b>	34	25.8%	
<b>30-39 Years</b>	56	42.4%	
<b>40-49 Years</b>	26	19.7%	
<b>50-59 Years</b>	16	12.1%	
<b>Total</b>	<b>132</b>	<b>100.0%</b>	

	# of Cases	% of Cases	
<b>Asian</b>		suppressed	
<b>Black</b>	29	22.0%	
<b>Hispanic</b>	48	36.4%	
<b>Other</b>		suppressed	
<b>Unknown</b>	6	4.5%	
<b>White</b>	44	33.3%	
<b>Total</b>	<b>132</b>	<b>100.0%</b>	

\*Case counts of 1-4 are suppressed to prevent potential identification of individuals. Additional cells have been suppressed to prevent back-calculation of small counts (complementary suppression).

# Current Situation (7/9/2023 - 10/7/2023)



TEXAS

Health and Human Services

Texas Department of State  
Health Services

- Preliminary data indicate a continued downward trend in cases.
- Over the past 3 months:
  - 15 of 16 (94%) cases were from PHR 2/3
  - All male
  - 31% of cases were White, 31% were Black or African American, and 24% were Hispanic
  - Almost half of the cases were between 40-49 years of age



# Interim Clinical Guidance for the Treatment of Mpox

- For patients with severe disease or at high risk for progression to severe disease, tecovirimat should be administered early in the course of illness along with supportive care and pain control.
- Medical Countermeasures (MCMs) are available for the treatment of mpox.

MCMs	ACCESS/APPROVAL	SOURCE/SHIPPED FROM
<b>Tecovirimat(TPOXX), Oral tablet</b>	STOMP trial / HPOP	Trial site / SNS
<b>Tecovirimat(TPOXX), IV</b>	CDC approval	SNS
<b>Brincidofovir, tablets or oral suspension</b>	FDA	SNS
<b>Cidofovir, IV</b>	Commercially available	
<b>Trifluridine ophthalmic solution (drops)</b>	Commercially available	
<b>Vaccinia immune globulin intravenous (VIGIV)</b>	CDC approval	SNS

- Email DSHS MPX Consult at [dshsmpxconsult@dshs.texas.gov](mailto:dshsmpxconsult@dshs.texas.gov) to request CDC clinical consult.
- Treatment Information for Healthcare Professionals: [Treatment Information for Healthcare Professionals | Mpox | Poxvirus | CDC](#)



TEXAS

Health and Human Services

Texas Department of State Health Services



# Interim Clinical Guidance for the Treatment of Mpox - Oral TPOXX Access



TEXAS

Health and Human Services

Texas Department of State  
Health Services

- Providers are encouraged to inform patients with mpox about the study of Tecovirimat for human monkeypox virus (STOMP) clinical trial.
- Access to oral tecovirimat is also available for patients with mpox who meet eligibility criteria (e.g., have severe disease or involvement of anatomic areas that might result in serious sequelae or are at high-risk for severe disease) under CDC's Expanded Access Investigational New Drug (EA-IND) protocol.
  - Send requests to [dshsmpxconsult@dshs.texas.gov](mailto:dshsmpxconsult@dshs.texas.gov)
- See CDC's [interim clinical guidance for the treatment of mpox](#) for complete description of treatment options.
- For more information about the STOMP trial, visit [stomptpox.org](http://stomptpox.org) or call 1-855-876-9997

# Mpox Vaccine (JYNNEOS)

- Route of vaccine administration based on the best option and individual preferences.
  - Providers can administer JYNNEOS either subcutaneously (0.5 mL/dose) or intradermally (0.1 mL/dose) to individuals  $\geq 18$  yrs.
  - Individual less than 18 years of age, administer subcutaneously only (0.5 mL/dose).
- JYNNEOS is a 2-dose vaccine series given 28 days apart regardless of route of administration.
  - Either route, the vaccine must be administered as a 2-dose series given 28 days apart.
  - If its longer than 28 days, administer the second dose as soon as possible. There is no need to repeat dose 1.



TEXAS

Health and Human Services

Texas Department of State  
Health Services

# Mpox Vaccine (JYNNEOS)



TEXAS  
Health and Human  
Services

Texas Department of State  
Health Services

- People may be vaccinated after exposure to Mpox virus to help prevent Mpox disease (i.e., post-exposure prophylaxis).
- Providers may request JYNNEOS through the DSHS vaccine allocation & ordering system (VAOS)
- Shipments are sent from the DSHS pharmacy warehouse.
- Individuals who are vaccinated should continue to take steps to protect themselves from infection by avoiding close, skin-to-skin contact, including intimate contact, with someone who has Mpox.



**TEXAS**  
Health and Human  
Services

---

**Texas Department of State  
Health Services**

**Thank you**

---